- Home
- TC vs NNVC Comparison
TC vs NNVC Comparison
Compare TC & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TC
- NNVC
- Stock Information
- Founded
- TC 2010
- NNVC 2005
- Country
- TC China
- NNVC United States
- Employees
- TC 116
- NNVC N/A
- Industry
- TC Business Services
- NNVC Biotechnology: Pharmaceutical Preparations
- Sector
- TC Consumer Discretionary
- NNVC Health Care
- Exchange
- TC Nasdaq
- NNVC Nasdaq
- Market Cap
- TC 25.0M
- NNVC 22.5M
- IPO Year
- TC 2018
- NNVC N/A
- Fundamental
- Price
- TC $14.83
- NNVC $1.42
- Analyst Decision
- TC
- NNVC
- Analyst Count
- TC 0
- NNVC 0
- Target Price
- TC N/A
- NNVC N/A
- AVG Volume (30 Days)
- TC 29.8K
- NNVC 112.7K
- Earning Date
- TC 08-29-2025
- NNVC 11-13-2025
- Dividend Yield
- TC N/A
- NNVC N/A
- EPS Growth
- TC N/A
- NNVC N/A
- EPS
- TC N/A
- NNVC N/A
- Revenue
- TC $5,115,721.00
- NNVC N/A
- Revenue This Year
- TC N/A
- NNVC N/A
- Revenue Next Year
- TC N/A
- NNVC N/A
- P/E Ratio
- TC N/A
- NNVC N/A
- Revenue Growth
- TC N/A
- NNVC N/A
- 52 Week Low
- TC $9.20
- NNVC $0.94
- 52 Week High
- TC $86.00
- NNVC $1.92
- Technical
- Relative Strength Index (RSI)
- TC 54.66
- NNVC 44.77
- Support Level
- TC $13.00
- NNVC $1.42
- Resistance Level
- TC $15.50
- NNVC $1.47
- Average True Range (ATR)
- TC 2.19
- NNVC 0.05
- MACD
- TC 0.26
- NNVC 0.00
- Stochastic Oscillator
- TC 30.22
- NNVC 46.67
About TC TuanChe Limited
Token Cat Ltd is an omnichannel automotive marketplace in China. The company operates in one segment, providing auto shows, special promotion event services, virtual dealerships, online marketing services, and more. It organizes auto shows to facilitate transactions between consumers and auto dealers, which include auto dealers, automakers, and automotive service providers. It offers services through its online platform and offline events.
About NNVC NanoViricides Inc.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.